|
NZ250844A
(en)
|
1993-04-07 |
1996-03-26 |
Pfizer |
Treatment of non-insulin dependant diabetes with peptides; composition
|
|
US6284727B1
(en)
|
1993-04-07 |
2001-09-04 |
Scios, Inc. |
Prolonged delivery of peptides
|
|
US5424286A
(en)
|
1993-05-24 |
1995-06-13 |
Eng; John |
Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
|
|
US5641757A
(en)
|
1994-12-21 |
1997-06-24 |
Ortho Pharmaceutical Corporation |
Stable 2-chloro-2'-deoxyadenosine formulations
|
|
CA2262647C
(en)
|
1996-08-08 |
2007-12-04 |
Amylin Pharmaceuticals, Inc. |
Methods for regulating gastrointestinal motility
|
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
DK0944648T3
(da)
|
1996-08-30 |
2007-07-02 |
Novo Nordisk As |
GLP-1 derivater
|
|
DE69831673C5
(de)
|
1997-01-07 |
2015-01-22 |
Amylin Pharmaceuticals, Llc |
Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
|
|
US6410511B2
(en)
|
1997-01-08 |
2002-06-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US7312196B2
(en)
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US6723530B1
(en)
|
1997-02-05 |
2004-04-20 |
Amylin Pharmaceuticals, Inc. |
Polynucleotides encoding proexendin, and methods and uses thereof
|
|
US7157555B1
(en)
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
|
ES2293688T5
(es)
|
1997-08-08 |
2011-05-04 |
Amylin Pharmaceuticals, Inc. |
Nuevos compuestos análogos de la exendina.
|
|
JP2003522721A
(ja)
|
1997-11-14 |
2003-07-29 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
新規なエキセンジンアゴニスト化合物
|
|
BR9814189A
(pt)
|
1997-11-14 |
2000-10-03 |
Amylin Pharmaceuticals Inc |
"compostos agonistas da exendina"
|
|
US7223725B1
(en)
|
1997-11-14 |
2007-05-29 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
|
US7220721B1
(en)
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
|
DK1044015T3
(da)
|
1998-01-09 |
2008-12-08 |
Amylin Pharmaceuticals Inc |
Formuleringer med amylinagonistpeptider og insulin
|
|
US6703359B1
(en)
|
1998-02-13 |
2004-03-09 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and GLP-1
|
|
AU3247799A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
|
EP1062229A1
(en)
|
1998-03-09 |
2000-12-27 |
Zealand Pharmaceuticals A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
|
AU2612599A
(en)
|
1998-03-13 |
1999-10-11 |
Novo Nordisk A/S |
Stabilized aqueous peptide solutions
|
|
US6998387B1
(en)
|
1998-03-19 |
2006-02-14 |
Amylin Pharmaceuticals, Inc. |
Human appetite control by glucagon-like peptide receptor binding compounds
|
|
PL195662B1
(pl)
|
1998-06-12 |
2007-10-31 |
Amylin Pharmaceuticals Inc |
Zastosowanie kompozycji zawierającej eksendynę albo związek do niej homologiczny
|
|
US7056734B1
(en)
|
1998-08-10 |
2006-06-06 |
The United States Of America As Represented By The Department Of Health And Human Services, Nih |
Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof
|
|
JP2002524514A
(ja)
|
1998-09-17 |
2002-08-06 |
イーライ・リリー・アンド・カンパニー |
タンパク質製剤
|
|
US7259136B2
(en)
|
1999-04-30 |
2007-08-21 |
Amylin Pharmaceuticals, Inc. |
Compositions and methods for treating peripheral vascular disease
|
|
US6429197B1
(en)
|
1998-10-08 |
2002-08-06 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
|
|
US6284725B1
(en)
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
|
AU2373400A
(en)
|
1998-12-22 |
2000-07-12 |
Eli Lilly And Company |
Shelf-stable formulation of glucagon-like peptide-1
|
|
US7399489B2
(en)
|
1999-01-14 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Exendin analog formulations
|
|
CA2356331C
(en)
|
1999-01-14 |
2009-10-13 |
Amylin Pharmaceuticals, Inc. |
Methods for glucagon suppression
|
|
ES2244416T5
(es)
|
1999-01-14 |
2020-01-03 |
Amylin Pharmaceuticals Llc |
Formulaciones novedosas de agonistas de la exendina y métodos de administración de los mismos
|
|
US20030087820A1
(en)
|
1999-01-14 |
2003-05-08 |
Young Andrew A. |
Novel exendin agonist formulations and methods of administration thereof
|
|
EP1956000B1
(en)
|
1999-03-17 |
2016-10-05 |
Novo Nordisk A/S |
Acylating agents useful for acylating peptides
|
|
US6451974B1
(en)
|
1999-03-17 |
2002-09-17 |
Novo Nordisk A/S |
Method of acylating peptides and novel acylating agents
|
|
BR0010705A
(pt)
|
1999-04-30 |
2002-02-05 |
Amylin Pharmaceuticals Inc |
Exendinas modificadas e agonistas da exendina
|
|
US6924264B1
(en)
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
|
ATE252601T1
(de)
|
1999-05-17 |
2003-11-15 |
Conjuchem Inc |
Lang wirkende insulinotrope peptide
|
|
US6849714B1
(en)
|
1999-05-17 |
2005-02-01 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
US6514500B1
(en)
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
|
US6482799B1
(en)
|
1999-05-25 |
2002-11-19 |
The Regents Of The University Of California |
Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
|
|
US6506724B1
(en)
|
1999-06-01 |
2003-01-14 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
|
|
US6344180B1
(en)
|
1999-06-15 |
2002-02-05 |
Bionebraska, Inc. |
GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
US6972319B1
(en)
|
1999-09-28 |
2005-12-06 |
Bayer Pharmaceuticals Corporation |
Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use
|
|
GB9930882D0
(en)
|
1999-12-30 |
2000-02-23 |
Nps Allelix Corp |
GLP-2 formulations
|
|
EP1246638B2
(en)
|
2000-01-10 |
2014-07-30 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the treatment of hypertriglyceridemia
|
|
EP1267912A2
(en)
|
2000-03-14 |
2003-01-02 |
Burkhard Göke |
Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
|
|
WO2001087322A2
(en)
|
2000-05-17 |
2001-11-22 |
Bionebraska, Inc. |
Peptide pharmaceutical formulations
|
|
CN103356996A
(zh)
|
2000-05-19 |
2013-10-23 |
埃米林药品公司 |
Glp-1用于制备治疗急性冠脉综合征的药物的用途
|
|
JP4624642B2
(ja)
|
2000-08-18 |
2011-02-02 |
エミスフェアー・テクノロジーズ・インク |
活性剤デリバリー用化合物および組成物
|
|
US7507714B2
(en)
|
2000-09-27 |
2009-03-24 |
Bayer Corporation |
Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use
|
|
DE60142351D1
(de)
|
2000-10-20 |
2010-07-22 |
Amylin Pharmaceuticals Inc |
Behandlung von hypoaktivem myokard und diabetischer herzmyopathie mit einem glp-1 peptid
|
|
SK288342B6
(en)
|
2000-12-07 |
2016-03-01 |
Lilly Co Eli |
GLP-1 fusion proteins
|
|
MXPA03005135A
(es)
|
2000-12-13 |
2003-12-04 |
Lilly Co Eli |
Regimen de tratamiento cronico usando peptidos insulinotropicos similares al glucagon.
|
|
GB2371227A
(en)
|
2001-01-10 |
2002-07-24 |
Grandis Biotech Gmbh |
Crystallisation - resistant aqueous growth hormone formulations
|
|
US6573237B2
(en)
|
2001-03-16 |
2003-06-03 |
Eli Lilly And Company |
Protein formulations
|
|
CN1162446C
(zh)
|
2001-05-10 |
2004-08-18 |
上海华谊生物技术有限公司 |
促胰岛素分泌肽衍生物
|
|
EP1542712A2
(en)
|
2001-06-01 |
2005-06-22 |
Eli Lilly And Company |
Glp-1 formulations with protracted time action
|
|
ATE382057T1
(de)
|
2001-06-28 |
2008-01-15 |
Novo Nordisk As |
Stabile formulierung von modifiziertem glp-1
|
|
CA2453434C
(en)
|
2001-07-16 |
2009-04-14 |
Hk Pharmaceuticals, Inc. |
Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
|
|
AU2002317599B2
(en)
|
2001-07-31 |
2008-04-03 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
GLP-1 exendin-4 peptide analogs and uses thereof
|
|
US7238663B2
(en)
|
2001-08-28 |
2007-07-03 |
Eli Lilly And Company |
Pre-mixes of GLP-1 and basal insulin
|
|
EP1448222A4
(en)
|
2001-10-19 |
2006-05-17 |
Lilly Co Eli |
BIPHASIC MIXTURES OF GLP-1 AND INSULIN
|
|
EP1463752A4
(en)
|
2001-12-21 |
2005-07-13 |
Human Genome Sciences Inc |
ALBUMIN FUSION PROTEINS
|
|
WO2003060071A2
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US7105489B2
(en)
|
2002-01-22 |
2006-09-12 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for treating polycystic ovary syndrome
|
|
NZ534125A
(en)
|
2002-02-20 |
2006-11-30 |
Emisphere Tech Inc |
A formulation comprising a GLP-1 compound and a delivery agent
|
|
DE60322513D1
(de)
|
2002-02-27 |
2008-09-11 |
Immunex Corp |
Stabilisierte TNFR-Fc Formulierung mit Arginin
|
|
WO2003077851A2
(en)
|
2002-03-11 |
2003-09-25 |
Hk Pharmaceuticals, Inc. |
Compounds and methods for analyzing the proteome
|
|
US7141240B2
(en)
|
2002-03-12 |
2006-11-28 |
Cedars-Sinai Medical Center |
Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
|
|
AU2003226913A1
(en)
|
2002-04-04 |
2003-10-20 |
Novo Nordisk A/S |
Glp-1 agonist and cardiovascular complications
|
|
MXPA04009929A
(es)
|
2002-04-10 |
2006-03-10 |
Lilly Co Eli |
Tratamiento de la gastroparesis.
|
|
US6861236B2
(en)
|
2002-05-24 |
2005-03-01 |
Applied Nanosystems B.V. |
Export and modification of (poly)peptides in the lantibiotic way
|
|
US20040037826A1
(en)
|
2002-06-14 |
2004-02-26 |
Michelsen Birgitte Koch |
Combined use of a modulator of CD3 and a GLP-1 compound
|
|
AU2003232172A1
(en)
|
2002-06-14 |
2003-12-31 |
Novo Nordisk A/S |
Combined use of a modulator of cd3 and a glp-1 compound
|
|
DE10227232A1
(de)
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
|
EP1525219B1
(en)
|
2002-07-04 |
2009-05-27 |
Zealand Pharma A/S |
Glp-1 and methods for treating diabetes
|
|
US20070065469A1
(en)
|
2002-07-09 |
2007-03-22 |
Michael Betz |
Liquid formulations with high concentration of human growth hormone (high) comprising glycine
|
|
WO2004004781A1
(en)
|
2002-07-09 |
2004-01-15 |
Sandoz Ag |
LIQUID FORMULATIONS WITH HIGH CONCENTRATION OF HUMAN GROWTH HORMONE (hgh) COMPRISING 1,2-PROLPYLENE GLYCOL
|
|
US20040038865A1
(en)
|
2002-08-01 |
2004-02-26 |
Mannkind Corporation |
Cell transport compositions and uses thereof
|
|
WO2004012672A2
(en)
|
2002-08-01 |
2004-02-12 |
Mannkind Corporation |
Cell transport compositions and uses thereof
|
|
US20080260838A1
(en)
|
2003-08-01 |
2008-10-23 |
Mannkind Corporation |
Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
|
|
ATE453644T1
(de)
|
2002-08-21 |
2010-01-15 |
Boehringer Ingelheim Pharma |
8-[3-amino-piperidin-1-yl] -xanthine, deren herstellung und deren verwendung als arzneimittel
|
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
AU2003268621B2
(en)
*
|
2002-10-02 |
2009-01-15 |
Zealand Pharma A/S |
Stabilized exendin-4 compounds
|
|
US20050209142A1
(en)
|
2002-11-20 |
2005-09-22 |
Goran Bertilsson |
Compounds and methods for increasing neurogenesis
|
|
AU2003280117B2
(en)
|
2002-11-20 |
2009-09-10 |
Newron Sweden Ab |
Compounds and methods for increasing neurogenesis
|
|
US6969702B2
(en)
|
2002-11-20 |
2005-11-29 |
Neuronova Ab |
Compounds and methods for increasing neurogenesis
|
|
US20040209803A1
(en)
|
2002-12-19 |
2004-10-21 |
Alain Baron |
Compositions for the treatment and prevention of nephropathy
|
|
EP1610811A4
(en)
|
2002-12-17 |
2008-03-26 |
Amylin Pharmaceuticals Inc |
PREVENTION AND TREATMENT OF CARDIAC ARRHYTHMIAS
|
|
US7790681B2
(en)
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
|
GB0300571D0
(en)
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
|
EP1620118B1
(en)
|
2003-04-08 |
2014-06-18 |
Yeda Research And Development Co., Ltd. |
Reversible pegylated drugs
|
|
WO2004089985A1
(en)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Stable pharmaceutical compositions
|
|
US7259234B2
(en)
|
2003-05-15 |
2007-08-21 |
Trustees Of Tufts College |
Stable analogs of peptide and polypeptide therapeutics
|
|
US7947261B2
(en)
|
2003-05-23 |
2011-05-24 |
Nektar Therapeutics |
Conjugates formed from polymer derivatives having particular atom arrangements
|
|
MXPA05007628A
(es)
|
2003-05-23 |
2005-10-19 |
Nektar Therapeutics Al Corp |
Derivados de polimeros que tienen arreglos de atomos particulares.
|
|
EP1631308B1
(en)
|
2003-05-30 |
2013-07-31 |
Amylin Pharmaceuticals, LLC |
Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
|
|
WO2004105790A1
(en)
|
2003-06-03 |
2004-12-09 |
Novo Nordisk A/S |
Stabilized pharmaceutical peptide compositions
|
|
KR101308912B1
(ko)
|
2003-06-03 |
2013-09-23 |
노보 노르디스크 에이/에스 |
안정화된 약학적 펩티드 조성물
|
|
PL1633390T3
(pl)
|
2003-06-03 |
2012-06-29 |
Novo Nordisk As |
Stabilizowane kompozycje farmaceutyczne peptydu glp-1
|
|
ATE529126T1
(de)
|
2003-06-03 |
2011-11-15 |
Novo Nordisk As |
Stabilisierte pharmazeutische peptid zusammensetzungen
|
|
US8921311B2
(en)
|
2003-08-01 |
2014-12-30 |
Mannkind Corporation |
Method for treating hyperglycemia
|
|
JP4463814B2
(ja)
|
2003-08-05 |
2010-05-19 |
ノボ ノルディスク アクティーゼルスカブ |
新規のインスリン誘導体
|
|
JP5622998B2
(ja)
|
2003-08-21 |
2014-11-12 |
ノヴォ ノルディスク アー／エス |
ラセミ化されたアミノ酸を含むポリペプチドの分離
|
|
US20060247167A1
(en)
|
2003-09-01 |
2006-11-02 |
Novo Nordisk A/S |
Stable formulations of peptides
|
|
JP5518282B2
(ja)
|
2003-09-01 |
2014-06-11 |
ノヴォ ノルディスク アー／エス |
安定なペプチドの製剤
|
|
JP2007537981A
(ja)
|
2003-09-19 |
2007-12-27 |
ノボ ノルディスク アクティーゼルスカブ |
新規の血漿タンパク質親和性タグ
|
|
US20060287221A1
(en)
|
2003-11-13 |
2006-12-21 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
|
|
ATE525083T1
(de)
|
2003-11-13 |
2011-10-15 |
Novo Nordisk As |
Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung
|
|
US20050281879A1
(en)
|
2003-11-14 |
2005-12-22 |
Guohua Chen |
Excipients in drug delivery vehicles
|
|
US20050106214A1
(en)
|
2003-11-14 |
2005-05-19 |
Guohua Chen |
Excipients in drug delivery vehicles
|
|
WO2005081619A2
(en)
|
2003-11-20 |
2005-09-09 |
Neuronova Ab |
Compounds and methods for increasing neurogenesis
|
|
SI1687019T1
(en)
|
2003-11-20 |
2018-04-30 |
Novo Nordisk A/S |
Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
|
|
EP1692168B1
(en)
|
2003-12-03 |
2011-07-20 |
Novo Nordisk A/S |
Single-chain insulin
|
|
JP2007513965A
(ja)
|
2003-12-10 |
2007-05-31 |
ネクター セラピューティクス アラバマ，コーポレイション |
ポリマー・活性剤複合体の二つの集団を含む組成物
|
|
US20050143303A1
(en)
|
2003-12-26 |
2005-06-30 |
Nastech Pharmaceutical Company Inc. |
Intranasal administration of glucose-regulating peptides
|
|
US20060210614A1
(en)
|
2003-12-26 |
2006-09-21 |
Nastech Pharmaceutical Company Inc. |
Method of treatment of a metabolic disease using intranasal administration of exendin peptide
|
|
CN1938334A
(zh)
|
2004-01-30 |
2007-03-28 |
瓦拉塔药品公司 |
Glp－1激动剂和胃泌素化合物的联合使用
|
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
|
US8114958B2
(en)
|
2004-02-11 |
2012-02-14 |
Amylin Pharmaceuticals, Inc. |
Amylin family peptides
|
|
EP2335715A3
(en)
|
2004-02-11 |
2013-12-18 |
Amylin Pharmaceuticals, LLC |
Pancreatic polypeptide family motifs and polypeptides comprising the same
|
|
AU2005211755B2
(en)
|
2004-02-11 |
2012-03-15 |
Amylin Pharmaceuticals, Llc |
Hybrid polypeptides with selectable properties
|
|
US7399744B2
(en)
|
2004-03-04 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Methods for affecting body composition
|
|
SI2409707T1
(sl)
|
2004-04-15 |
2015-07-31 |
Alkermes Pharma Ireland Limited |
Naprava s podaljšanim sproščanjem na osnovi polimerov
|
|
US20060110423A1
(en)
|
2004-04-15 |
2006-05-25 |
Wright Steven G |
Polymer-based sustained release device
|
|
US7456254B2
(en)
|
2004-04-15 |
2008-11-25 |
Alkermes, Inc. |
Polymer-based sustained release device
|
|
US20090069226A1
(en)
|
2004-05-28 |
2009-03-12 |
Amylin Pharmaceuticals, Inc. |
Transmucosal delivery of peptides and proteins
|
|
WO2005117584A2
(en)
|
2004-05-28 |
2005-12-15 |
Amylin Pharmaceuticals, Inc |
Improved transmucosal delivery of peptides and proteins
|
|
CN1950078A
(zh)
|
2004-06-11 |
2007-04-18 |
诺和诺德公司 |
使用glp－1激动剂抵抗药物诱发的肥胖
|
|
WO2006014673A2
(en)
|
2004-07-19 |
2006-02-09 |
Nobex Corporation |
Insulin-oligomer conjugates, formulations and uses thereof
|
|
JP2008507280A
(ja)
|
2004-07-21 |
2008-03-13 |
アンブレツクス・インコーポレイテツド |
非天然コードアミノ酸を用いた生合成ポリペプチド
|
|
EP1814599A4
(en)
|
2004-08-03 |
2008-12-17 |
Biorexis Pharmaceutical Corp |
COMBINATION THERAPY WITH TRANSFERRIN FUSION PROTEINS WITH GLP-1
|
|
WO2006024631A2
(en)
|
2004-08-31 |
2006-03-09 |
Novo Nordisk A/S |
Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
|
|
DE102004043153B4
(de)
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
|
EP1791554A2
(en)
|
2004-09-17 |
2007-06-06 |
Novo Nordisk A/S |
Pharmaceutical compositions containing insulin and insulinotropic peptide
|
|
BRPI0516830A
(pt)
|
2004-10-01 |
2008-09-23 |
Ramscor Inc |
composições de droga de liberação sustentada convenientemente implantáveis
|
|
EP2330126B1
(en)
|
2004-10-07 |
2015-12-23 |
Novo Nordisk A/S |
Protracted exendin-4 compounds
|
|
US7595294B2
(en)
|
2004-10-08 |
2009-09-29 |
Transition Therapeutics, Inc. |
Vasoactive intestinal polypeptide pharmaceuticals
|
|
US20090036355A1
(en)
|
2004-10-13 |
2009-02-05 |
Sanjay Bhanot |
Antisense Modulation of PTP1B Expression
|
|
US7442682B2
(en)
|
2004-10-19 |
2008-10-28 |
Nitto Denko Corporation |
Transepithelial delivery of peptides with incretin hormone activities
|
|
EP2494983B1
(en)
|
2004-11-12 |
2019-04-24 |
Novo Nordisk A/S |
Stable formulations of glp-1
|
|
US20080125361A1
(en)
|
2004-11-12 |
2008-05-29 |
Novo Nordisk A/S |
Stable Formulations Of Peptides
|
|
WO2006051103A2
(en)
|
2004-11-12 |
2006-05-18 |
Novo Nordisk A/S |
Stable formulations of peptides
|
|
KR20070094909A
(ko)
|
2004-12-02 |
2007-09-27 |
도만티스 리미티드 |
혈청 알부민 및 ｇｌｐ-1 또는 ｐｙｙ를 표적으로 삼는이중특이성 도메인을 갖는 항체
|
|
EP3000826A1
(en)
|
2004-12-13 |
2016-03-30 |
Amylin Pharmaceuticals, LLC |
Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
|
|
AU2005318984B2
(en)
|
2004-12-21 |
2011-12-01 |
Nektar Therapeutics |
Stabilized polymeric thiol reagents
|
|
MX2007007565A
(es)
|
2004-12-22 |
2007-07-24 |
Lilly Co Eli |
Formulaciones de proteina de fusion analoga del peptido-1similar al glucagon (glp-1).
|
|
AU2005323063B2
(en)
|
2004-12-24 |
2011-01-27 |
Amylin Pharmaceuticals, Llc |
Use of GLP-1 and agonists thereof to prevent cardiac myocyte apoptosis
|
|
JP4785206B2
(ja)
|
2005-01-14 |
2011-10-05 |
ウクスィ・グランドチャンプ・ファーマシューティカル・テクノロジー・カンパニー・リミテッド |
修飾されたエキセンディン（Ｅｘｅｎｄｉｎｓ）及びその使用
|
|
US8716221B2
(en)
|
2005-01-14 |
2014-05-06 |
Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. |
Modified exendins and uses thereof
|
|
US20080233053A1
(en)
|
2005-02-07 |
2008-09-25 |
Pharmalight Inc. |
Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
|
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
|
MX2007009760A
(es)
|
2005-02-11 |
2007-11-07 |
Amylin Pharmaceuticals Inc |
Polipeptidos del analogo e hibrido del peptido inhibidor gastrico con propiedades seleccionables.
|
|
WO2006097535A2
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Peptide agonists of the glucagon family with secretin like activity
|
|
US8946149B2
(en)
|
2005-04-11 |
2015-02-03 |
Amylin Pharmaceuticals, Llc |
Use of exendin and analogs thereof to delay or prevent cardiac remodeling
|
|
US20090043264A1
(en)
|
2005-04-24 |
2009-02-12 |
Novo Nordisk A/S |
Injection Device
|
|
US8097584B2
(en)
|
2005-05-25 |
2012-01-17 |
Novo Nordisk A/S |
Stabilized formulations of insulin that comprise ethylenediamine
|
|
TW200716679A
(en)
|
2005-05-26 |
2007-05-01 |
Bristol Myers Squibb Co |
N-terminally modified GLP-1 receptor modulators
|
|
JP5198261B2
(ja)
|
2005-06-06 |
2013-05-15 |
カムルス エービー |
Ｇｌｐ−１類似体製剤
|
|
GB0511986D0
(en)
|
2005-06-13 |
2005-07-20 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
|
SI1891105T1
(sl)
*
|
2005-06-13 |
2012-07-31 |
Imp Innovations Ltd |
Analogi oksintomodulina in njihovi učinki na prehranjevalno vedenje
|
|
CA2611823C
(en)
|
2005-06-16 |
2013-07-30 |
Nektar Therapeutics Al, Corporation |
Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
|
|
KR20080033439A
(ko)
|
2005-08-04 |
2008-04-16 |
넥타르 테라퓨틱스 에이엘, 코포레이션 |
Ｇ-ｃｓｆ 부분 및 중합체의 컨주게이트
|
|
CA2658678A1
(en)
|
2005-08-06 |
2007-02-15 |
Gerald J. Prud'homme |
Composition and method for prevention and treatment of type i diabetes
|
|
EP2330124B1
(en)
|
2005-08-11 |
2015-02-25 |
Amylin Pharmaceuticals, LLC |
Hybrid polypeptides with selectable properties
|
|
SI3524261T1
(sl)
|
2005-08-19 |
2024-02-29 |
Amylin Pharmaceuticals, Llc |
Exendin za uporabo pri zdravljenju sladkorne bolezni in zmanjševanju telesne teže
|
|
WO2007033372A2
(en)
|
2005-09-14 |
2007-03-22 |
Mannkind Corporation |
Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
|
|
ATE514435T1
(de)
|
2005-09-20 |
2011-07-15 |
Novartis Pharma Gmbh |
Verwendung eines dpp-iv-hemmers zur minderung hypoglykämischer ereignisse
|
|
WO2007047834A2
(en)
|
2005-10-18 |
2007-04-26 |
Biocon Limited |
Oral peptide conjugates for metabolic diseases
|
|
WO2007047997A2
(en)
|
2005-10-19 |
2007-04-26 |
Smartcells, Inc. |
Methods for reducing the mitogenicity of lectin compositions
|
|
US8338368B2
(en)
|
2005-11-07 |
2012-12-25 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
|
US8039432B2
(en)
|
2005-11-09 |
2011-10-18 |
Conjuchem, Llc |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
|
|
WO2007064691A1
(en)
|
2005-12-02 |
2007-06-07 |
Nabil Habib Lab |
Treatment of cancer and other diseases
|
|
JP2009518315A
(ja)
|
2005-12-02 |
2009-05-07 |
エムディーアールエヌエー，インコーポレイテッド |
グルコース調節ペプチドの上皮透過性を増大させるための製剤処方
|
|
RU2008124109A
(ru)
|
2005-12-08 |
2010-01-20 |
МДРНА, Инк. (US) |
Чресслизистая доставка стабилизированных композиций эксендина
|
|
JP5096363B2
(ja)
|
2005-12-16 |
2012-12-12 |
ネクター セラピューティックス |
Ｇｌｐ−１のポリマ複合体
|
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
|
ES2779992T3
(es)
|
2005-12-20 |
2020-08-21 |
Univ Duke |
Métodos y composiciones para suministrar agentes activos con propiedades farmacológicas potenciadas
|
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
|
MX2008009125A
(es)
|
2006-01-18 |
2008-10-23 |
Qps Llc |
Composiciones farmaceuticas con estabilidad mejorada.
|
|
KR20080098504A
(ko)
|
2006-02-03 |
2008-11-10 |
메디뮨 엘엘씨 |
단백질 제제
|
|
US7704953B2
(en)
|
2006-02-17 |
2010-04-27 |
Mdrna, Inc. |
Phage displayed cell binding peptides
|
|
JP5412273B2
(ja)
|
2006-03-21 |
2014-02-12 |
アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー |
ペプチド−ぺプチダーゼ阻害剤及びその使用
|
|
CA2648440A1
(en)
|
2006-04-13 |
2007-10-25 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. . |
Pharmaceutical compositions of hglp-1, exendin-4 and analogs thereof
|
|
RU2542500C2
(ru)
|
2006-04-14 |
2015-02-20 |
Маннкайнд Корпорейшн |
Фармацевтические композиции, содержащие глюкагон-подобный пептид 1 (glp-1)
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
US8299024B2
(en)
|
2006-05-12 |
2012-10-30 |
Amylin Pharmaceuticals, Llc |
Methods to restore glycemic control
|
|
EP2021014A1
(en)
|
2006-05-26 |
2009-02-11 |
Brystol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
|
MX2008015107A
(es)
|
2006-05-26 |
2008-12-09 |
Amylin Pharmaceuticals Inc |
Composicion y metodos para el tratamiento de insuficiecia cardiaca congestiva.
|
|
PT2038423E
(pt)
|
2006-06-21 |
2013-03-27 |
Biocon Ltd |
Método de produção de um polipéptido biologicamente activo possuindo actividade insulinotrópica
|
|
ES2530390T3
(es)
|
2006-07-05 |
2015-03-02 |
Foamix Pharmaceuticals Ltd |
Vehículo espumante de ácido carboxílico y composiciones farmacéuticas del mismo
|
|
CN101511868B
(zh)
|
2006-07-24 |
2013-03-06 |
比奥雷克西斯制药公司 |
毒蜥外泌肽融合蛋白
|
|
US7928186B2
(en)
|
2006-08-02 |
2011-04-19 |
Phoenix Pharmaceuticals, Inc. |
Cell permeable bioactive peptide conjugates
|
|
AU2007281433A1
(en)
|
2006-08-04 |
2008-02-07 |
Nastech Pharmaceutical Company Inc. |
Compositions for intranasal delivery of human insulin and uses thereof
|
|
PL2359808T3
(pl)
|
2006-08-09 |
2013-10-31 |
Intarcia Therapeutics Inc |
Osmotyczne systemy dostawcze i zespoły tłokowe
|
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
|
EP2057188B1
(en)
|
2006-08-17 |
2013-07-31 |
Amylin Pharmaceuticals, LLC |
Dpp-iv resistant gip hybrid polypeptides with selectable properties
|
|
WO2008023050A1
(en)
*
|
2006-08-25 |
2008-02-28 |
Novo Nordisk A/S |
Acylated exendin-4 compounds
|
|
CN101125207B
(zh)
|
2006-11-14 |
2012-09-05 |
上海华谊生物技术有限公司 |
带有聚乙二醇基团的艾塞丁或其类似物及其制剂和用途
|
|
CN101605530A
(zh)
|
2006-12-12 |
2009-12-16 |
安米林药品公司 |
药物制剂及其制备方法
|
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
|
JP5890085B2
(ja)
|
2007-01-05 |
2016-03-22 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ |
生理学的ｐＨの緩衝液中で向上した溶解度を示すグルカゴン類縁体
|
|
US20090098130A1
(en)
*
|
2007-01-05 |
2009-04-16 |
Bradshaw Curt W |
Glucagon-like protein-1 receptor (glp-1r) agonist compounds
|
|
CN101663317A
(zh)
|
2007-01-05 |
2010-03-03 |
CovX科技爱尔兰有限公司 |
胰高血糖素样蛋白-1受体glp-1r激动剂化合物
|
|
RU2432361C2
(ru)
|
2007-01-05 |
2011-10-27 |
КовЭкс Текнолоджиз Айэлэнд Лимитед |
Соединения агонисты рецептора глюкагоноподобного белка-1 (glp-1r)
|
|
WO2008098212A2
(en)
|
2007-02-08 |
2008-08-14 |
Diobex, Inc. |
Extended release formulations of glucagon and other peptides and proteins
|
|
GEP20135944B
(en)
|
2007-02-15 |
2013-10-25 |
Indiana Unversity Research And Tech Corporation |
Glucagon/glp-1 receptor co-agonists
|
|
WO2008130066A1
(en)
|
2007-04-20 |
2008-10-30 |
Kang Choon Lee |
Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
|
|
JP5351884B2
(ja)
|
2007-04-23 |
2013-11-27 |
インターシア セラピューティクス，インコーポレイティド |
インスリン分泌促進性ペプチドの懸濁製剤及び使用
|
|
WO2008134425A1
(en)
|
2007-04-27 |
2008-11-06 |
Cedars-Sinai Medical Center |
Use of glp-1 receptor agonists for the treatment of gastrointestinal disorders
|
|
US7829664B2
(en)
|
2007-06-01 |
2010-11-09 |
Boehringer Ingelheim International Gmbh |
Modified nucleotide sequence encoding glucagon-like peptide-1 (GLP-1), nucleic acid construct comprising same for production of glucagon-like peptide-1 (GLP-1), human cells comprising said construct and insulin-producing constructs, and methods of use thereof
|
|
CA2689909C
(en)
|
2007-06-08 |
2016-04-05 |
Ascendis Pharma As |
Long-acting polymeric prodrugs of exendin
|
|
EP2158214B1
(en)
|
2007-06-15 |
2011-08-17 |
Zealand Pharma A/S |
Glucagon analogues
|
|
CA2691695C
(en)
|
2007-07-10 |
2014-03-18 |
Eli Lilly And Company |
Glp-1-fc fusion protein formulation
|
|
US20110034373A1
(en)
|
2007-08-03 |
2011-02-10 |
Eli Lilly And Company |
Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
|
|
CN101366692A
(zh)
|
2007-08-15 |
2009-02-18 |
江苏豪森药业股份有限公司 |
一种稳定的艾塞那肽制剂
|
|
SI2193142T1
(sl)
|
2007-08-30 |
2015-05-29 |
Curedm Group Holdings, Llc |
Sestavek in postopek za uporabo proislet peptidov in analogov le-teh
|
|
EP2190460B1
(en)
|
2007-09-05 |
2014-12-17 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
|
WO2009035540A2
(en)
|
2007-09-07 |
2009-03-19 |
Ipsen Pharma S.A.S. |
Analogues of exendin-4 and exendin-3
|
|
US8785396B2
(en)
|
2007-10-24 |
2014-07-22 |
Mannkind Corporation |
Method and composition for treating migraines
|
|
PL2211842T3
(pl)
|
2007-10-24 |
2015-12-31 |
Mannkind Corp |
Preparat suchego proszku do inhalacji zawierający glp-1 do stosowania w leczeniu hiperglikemii i cukrzycy w podawaniu płucnym
|
|
EP2214647A2
(en)
|
2007-10-24 |
2010-08-11 |
MannKind Corporation |
Delivery of active agents
|
|
AU2008318986B2
(en)
|
2007-10-30 |
2014-12-04 |
Indiana University Research And Technology Corporation |
Glucagon antagonists
|
|
EP2214691B1
(en)
|
2007-10-30 |
2015-09-30 |
Indiana University Research and Technology Corporation |
Compounds exhibiting glucagon antagonist and glp-1 agonist activity
|
|
PL2597103T3
(pl)
|
2007-11-16 |
2017-04-28 |
Novo Nordisk A/S |
Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec
|
|
WO2009067268A1
(en)
|
2007-11-23 |
2009-05-28 |
Michael Rothkopf |
Methods of enhancing diabetes resolution
|
|
CN101444618B
(zh)
|
2007-11-26 |
2012-06-13 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
|
CN102026666B
(zh)
|
2007-12-11 |
2013-10-16 |
常山凯捷健生物药物研发（河北）有限公司 |
促胰岛素肽缀合物制剂
|
|
MY152979A
(en)
|
2008-01-09 |
2014-12-15 |
Sanofi Aventis Deutschland |
Novel insulin derivatives having an extremely delayed time-action profile
|
|
JP2011511778A
(ja)
|
2008-01-30 |
2011-04-14 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション |
エステルに基づいたペプチドプロドラッグ
|
|
SI2237799T1
(sl)
|
2008-02-01 |
2019-07-31 |
Ascendis Pharma A/S |
Predzdravilo, ki obsega samo-cepljiv linker
|
|
WO2009113099A2
(en)
|
2008-02-06 |
2009-09-17 |
Biocon Limited |
Fermentation medias and processes thereof
|
|
WO2009114959A1
(zh)
|
2008-03-20 |
2009-09-24 |
中国人民解放军军事医学科学院毒物药物研究所 |
可注射用缓释药物制剂及其制备方法
|
|
JP2011516541A
(ja)
|
2008-04-07 |
2011-05-26 |
ナショナル インスティテュート オブ イミュノロジー |
糖尿病および他の慢性疾患の治療に有用な組成物
|
|
KR20110007242A
(ko)
|
2008-05-07 |
2011-01-21 |
메리온 리서치 Ⅲ 리미티드 |
펩티드 조성물 및 그의 제조 방법
|
|
EP2303313B1
(en)
|
2008-05-21 |
2015-10-28 |
Amylin Pharmaceuticals, LLC |
Exendins to lower cholestrol and triglycerides
|
|
US8329419B2
(en)
|
2008-05-23 |
2012-12-11 |
Amylin Pharmaceuticals, Llc |
GLP-1 receptor agonist bioassays
|
|
SG10201507036TA
(en)
|
2008-06-13 |
2015-10-29 |
Mannkind Corp |
A dry powder inhaler and system for drug delivery
|
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
|
CN102083854A
(zh)
|
2008-06-17 |
2011-06-01 |
大塚化学株式会社 |
附加了糖链的glp-1肽
|
|
BRPI0915282A2
(pt)
|
2008-06-17 |
2017-02-07 |
Univ Indiana Res & Tech Corp |
agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade
|
|
MX337038B
(es)
|
2008-06-17 |
2016-02-10 |
Univ Indiana Res & Tech Corp |
Co-antagonistas de receptor de glucagon/glp-1.
|
|
TWI541023B
(zh)
|
2008-06-17 |
2016-07-11 |
印第安納大學科技研究公司 |
在生理ｐｈ緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物
|
|
CA2726894A1
(en)
|
2008-06-27 |
2009-12-30 |
Duke University |
Therapeutic agents comprising elastin-like peptides
|
|
EP2303247A4
(en)
|
2008-07-21 |
2012-08-01 |
Syneron Medical Ltd |
TRANSDERMALES SYSTEM FOR THE EXTENDED RELEASE OF INCRETINS AND INCRETIN MIMETIC PEPTIDES
|
|
WO2010013012A2
(en)
|
2008-08-01 |
2010-02-04 |
Lund University Bioscience Ab |
Novel polypeptides and uses thereof
|
|
CN101670096B
(zh)
|
2008-09-11 |
2013-01-16 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
|
BRPI0920881B1
(pt)
|
2008-10-17 |
2021-09-21 |
Sanofi-Aventis Deutschland Gmbh |
Composição farmacêutica, seu uso e método de preparação da mesma, kit e dispositivo
|
|
LT2373681T
(lt)
|
2008-12-10 |
2017-04-10 |
Glaxosmithkline Llc |
Albiglutido farmacinės kompozicijos
|
|
ES2439499T3
(es)
|
2008-12-15 |
2014-01-23 |
Zealand Pharma A/S |
Análogos de glucagón
|
|
JP5635529B2
(ja)
|
2008-12-15 |
2014-12-03 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン類似体
|
|
JP5635530B2
(ja)
|
2008-12-15 |
2014-12-03 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン類似体
|
|
EA020596B1
(ru)
|
2008-12-15 |
2014-12-30 |
Зилэнд Фарма А/С |
Аналоги глюкагона
|
|
WO2010071807A1
(en)
|
2008-12-19 |
2010-06-24 |
Indiana University Research And Technology Corporation |
Amide based glucagon superfamily peptide prodrugs
|
|
CN101538323B
(zh)
|
2009-01-13 |
2012-05-09 |
深圳翰宇药业股份有限公司 |
一种纯化艾塞那肽的方法
|
|
WO2010096052A1
(en)
|
2009-02-19 |
2010-08-26 |
Merck Sharp & Dohme Corp. |
Oxyntomodulin analogs
|
|
CA2791847C
(en)
|
2009-03-04 |
2017-05-02 |
Mannkind Corporation |
An improved dry powder drug delivery system
|
|
JP5608686B2
(ja)
|
2009-03-05 |
2014-10-15 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
後退可能な針を備えた薬物送達デバイス
|
|
WO2010120476A2
(en)
|
2009-04-01 |
2010-10-21 |
Amylin Pharmaceuticals, Inc. |
N-terminus conformationally constrained glp-1 receptor agonist compounds
|
|
WO2010118034A2
(en)
|
2009-04-06 |
2010-10-14 |
Board Of Regents, The University Of Texas System |
Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells
|
|
CA2758445C
(en)
|
2009-04-22 |
2016-02-16 |
Alteogen, Inc. |
In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasing in vivo half-life using same
|
|
CN101870728A
(zh)
|
2009-04-23 |
2010-10-27 |
派格生物医药(苏州)有限公司 |
新型Exendin变体及其缀合物
|
|
CN101559041B
(zh)
|
2009-05-19 |
2014-01-15 |
中国科学院过程工程研究所 |
粒径均一的多肽药物缓释微球或微囊制剂及制备方法
|
|
JP5698223B2
(ja)
|
2009-05-20 |
2015-04-08 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
薬物送達デバイスにおける薬物含有カートリッジ用の栓
|
|
EP2432527B1
(en)
|
2009-05-20 |
2019-10-02 |
Sanofi-Aventis Deutschland GmbH |
A system comprising a drug delivery device and a cartridge provided with a bung and a method of identifying the cartridge
|
|
WO2010138671A1
(en)
|
2009-05-28 |
2010-12-02 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonist compounds for sleep enhancement
|
|
US20120172298A1
(en)
|
2009-06-11 |
2012-07-05 |
Novo Nordisk A/S |
Glp-1 and fgf21 combinations for treatment of diabetes type 2
|
|
MX2011013625A
(es)
|
2009-06-16 |
2012-01-20 |
Univ Indiana Res & Tech Corp |
Compuestos glucagon activo de receptor de gip.
|
|
CA2766537A1
(en)
|
2009-07-02 |
2011-01-06 |
Angiochem Inc. |
Multimeric peptide conjugates and uses thereof
|
|
DK2454282T3
(en)
|
2009-07-13 |
2015-05-04 |
Zealand Pharma As |
acetylated glucagonanaloger
|
|
CN101601646B
(zh)
|
2009-07-22 |
2011-03-23 |
南京凯瑞尔纳米生物技术有限公司 |
治疗糖尿病的鼻腔滴剂及其制备方法
|
|
WO2011011675A1
(en)
|
2009-07-23 |
2011-01-27 |
Zelos Therapeutics, Inc. |
Pharmaceutically acceptable formulations/compositions for peptidyl drugs
|
|
CN102548583B
(zh)
|
2009-07-31 |
2015-04-22 |
赛诺菲-安万特德国有限公司 |
包含胰岛素连接物缀合物的前药
|
|
WO2011016030A1
(en)
|
2009-08-03 |
2011-02-10 |
Technion Research & Development Foundation Ltd. |
Hydrogen production by an autothermal heat exchanger packed-bed membrane gas reformer
|
|
WO2011017835A1
(en)
|
2009-08-11 |
2011-02-17 |
Nanjing University |
Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
|
|
CN101993485B
(zh)
|
2009-08-20 |
2013-04-17 |
重庆富进生物医药有限公司 |
促胰岛素分泌肽类似物同源二聚体及其用途
|
|
US20120148586A1
(en)
|
2009-08-27 |
2012-06-14 |
Joyce Ching Tsu Chou |
Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
|
|
MX2012003939A
(es)
|
2009-09-30 |
2012-07-30 |
Glaxo Group Ltd |
Fusiones y conjugados de farmaco.
|
|
EP2490708B1
(en)
|
2009-10-22 |
2013-03-27 |
Biodel Inc. |
Stabilized glucagon solutions
|
|
US20110097386A1
(en)
|
2009-10-22 |
2011-04-28 |
Biodel, Inc. |
Stabilized glucagon solutions
|
|
US9610329B2
(en)
|
2009-10-22 |
2017-04-04 |
Albireo Pharma, Inc. |
Stabilized glucagon solutions
|
|
US20120264684A1
(en)
|
2009-10-30 |
2012-10-18 |
Yasuhiro Kajihara |
Glycosylated Form of Antigenic GLP-1 Analogue
|
|
KR101426180B1
(ko)
|
2009-11-02 |
2014-07-31 |
화이자 인코포레이티드 |
디옥사-비시클로［3.2.1］옥탄-2,3,4-트리올 유도체
|
|
EP2496249B1
(en)
|
2009-11-03 |
2016-03-09 |
Amylin Pharmaceuticals, LLC |
Glp-1 receptor agonist for use in treating obstructive sleep apnea
|
|
DK2498802T3
(en)
|
2009-11-13 |
2015-04-13 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
|
|
NZ599847A
(en)
|
2009-11-13 |
2013-09-27 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a glp-1 agonist and methionine
|
|
WO2011084459A1
(en)
|
2009-12-15 |
2011-07-14 |
Metabolic Solutions Development Company |
Ppar-sparing thiazolidinediones and combinations for the treatment of obesity and other metabolic diseases
|
|
NO2513070T3
(enExample)
|
2009-12-15 |
2018-04-07 |
|
|
|
KR20120103711A
(ko)
|
2009-12-15 |
2012-09-19 |
메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 |
신경퇴행성 질환의 치료를 위한 ｐｐａｒ 절약형 티아졸리딘디온 및 복합제
|
|
KR20120092712A
(ko)
|
2009-12-15 |
2012-08-21 |
메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 |
진성 당뇨병 및 다른 대사성 질환의 치료를 위한 ｐｐａｒ 절약형 티아졸리딘디온 및 복합제
|
|
WO2011073328A1
(en)
|
2009-12-16 |
2011-06-23 |
Novo Nordisk A/S |
Glp-1 receptor agonist compounds with a modified n-terminus
|
|
WO2011075623A1
(en)
|
2009-12-18 |
2011-06-23 |
Latitude Pharmaceuticals, Inc. |
One - phase gel compos ition compri s ing phos pholi pids
|
|
EP2512503A4
(en)
|
2009-12-18 |
2013-08-21 |
Univ Indiana Res & Tech Corp |
COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
|
|
CN101798588B
(zh)
|
2009-12-21 |
2015-09-09 |
上海仁会生物制药股份有限公司 |
Glp-1受体激动剂生物学活性测定方法
|
|
AR079344A1
(es)
|
2009-12-22 |
2012-01-18 |
Lilly Co Eli |
Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
|
|
AR079345A1
(es)
|
2009-12-22 |
2012-01-18 |
Lilly Co Eli |
Analogo peptidico de oxintomodulina
|
|
PH12012501494A1
(en)
|
2010-01-20 |
2012-10-22 |
Zealand Pharma As |
Treatment of cardiac conditions
|
|
JP2013518115A
(ja)
|
2010-01-27 |
2013-05-20 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション |
代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐ｇｉｐアゴニスト複合体及び組成物
|
|
CA2786861A1
(en)
|
2010-02-01 |
2011-08-04 |
Sanofi-Aventis Deutschland Gmbh |
Cartridge holder, drug delivery device and method for securing a cartridge in a cartridge holder
|
|
WO2011109784A1
(en)
|
2010-03-05 |
2011-09-09 |
Conjuchem, Llc |
Formulation of insulinotropic peptide conjugates
|
|
CA2792663A1
(en)
|
2010-03-26 |
2011-09-29 |
Novo Nordisk A/S |
Novel glucagon analogues
|
|
AR080592A1
(es)
|
2010-03-26 |
2012-04-18 |
Lilly Co Eli |
Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
|
|
WO2011143208A1
(en)
|
2010-05-13 |
2011-11-17 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
|
|
RU2604067C2
(ru)
|
2010-05-13 |
2016-12-10 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Пептиды глюкагонового суперсемейства, обладающие активностью относительно ядерных гормональных рецепторов
|
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
|
JP2013529080A
(ja)
|
2010-05-20 |
2013-07-18 |
グラクソ グループ リミテッド |
改良された抗血清アルブミン結合変異体
|
|
EP2578726B1
(en)
|
2010-05-31 |
2018-10-17 |
JTEKT Corporation |
Method for manufacturing a coated member
|
|
CN102906981B
(zh)
|
2010-06-01 |
2016-03-16 |
本田技研工业株式会社 |
Dc/dc转换器的控制装置
|
|
US8263554B2
(en)
|
2010-06-09 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
Methods of using GLP-1 receptor agonists to treat pancreatitis
|
|
CN101891823B
(zh)
|
2010-06-11 |
2012-10-03 |
北京东方百泰生物科技有限公司 |
一种Exendin-4及其类似物融合蛋白
|
|
US8636711B2
(en)
|
2010-06-14 |
2014-01-28 |
Legacy Emanuel Hospital & Health Center |
Stabilized glucagon solutions and uses therefor
|
|
EP2582421A1
(en)
|
2010-06-21 |
2013-04-24 |
MannKind Corporation |
Dry powder drug delivery system and methods
|
|
UY33462A
(es)
|
2010-06-23 |
2012-01-31 |
Zealand Pharma As |
Analogos de glucagon
|
|
JP2013540102A
(ja)
|
2010-06-24 |
2013-10-31 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション |
アミド結合を介して修飾されたグルカゴンスーパーファミリーのペプチドプロドラッグ
|
|
US9234023B2
(en)
|
2010-06-24 |
2016-01-12 |
Biousian Biosystems, Inc. |
Glucagon-like peptide-1 glycopeptides
|
|
WO2011163473A1
(en)
|
2010-06-25 |
2011-12-29 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
|
|
WO2012012352A2
(en)
|
2010-07-19 |
2012-01-26 |
Amidebio, Llc |
Modified peptides and proteins
|
|
WO2012012460A1
(en)
|
2010-07-19 |
2012-01-26 |
Xeris Pharmaceuticals, Inc. |
Stable glucagon formulations for the treatment of hypoglycemia
|
|
WO2012015975A2
(en)
|
2010-07-28 |
2012-02-02 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonist compounds having stabilized regions
|
|
CN102397558B
(zh)
|
2010-09-09 |
2013-08-14 |
中国人民解放军军事医学科学院毒物药物研究所 |
Exendin-4类似物的定位聚乙二醇化修饰物及其用途
|
|
EP2438930A1
(en)
|
2010-09-17 |
2012-04-11 |
Sanofi-Aventis Deutschland GmbH |
Prodrugs comprising an exendin linker conjugate
|
|
JP6121330B2
(ja)
|
2010-09-28 |
2017-04-26 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
作用持続時間が増した改変ポリペプチド
|
|
JP5894174B2
(ja)
|
2010-11-03 |
2016-03-23 |
アレコー リミテッド |
グルカゴンを含む新規組成物
|
|
CN103200940A
(zh)
|
2010-11-09 |
2013-07-10 |
曼金德公司 |
用于治疗偏头痛的包含血清素受体激动剂和二酮哌嗪的组合物
|
|
EP2460552A1
(en)
|
2010-12-06 |
2012-06-06 |
Sanofi-Aventis Deutschland GmbH |
Drug delivery device with locking arrangement for dose button
|
|
CN102552883B
(zh)
|
2010-12-09 |
2014-02-19 |
天津药物研究院 |
一种多肽复合物、药物组合物、其制备方法和应用
|
|
AU2011343190B2
(en)
|
2010-12-16 |
2016-12-08 |
Novo Nordisk A/S |
Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
|
|
EP2654773B1
(en)
|
2010-12-22 |
2018-10-03 |
Indiana University Research and Technology Corporation |
Glucagon analogs exhibiting gip receptor activity
|
|
EP2654767A4
(en)
|
2010-12-22 |
2014-05-21 |
Amylin Pharmaceuticals Inc |
GLP-1 RECEPTOR AGONISTS FOR ISLAND CELL TRANSPLANTATION
|
|
CN102532301B
(zh)
|
2010-12-31 |
2014-09-03 |
上海医药工业研究院 |
一类新型的Exendin-4类似物及其制备方法
|
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
|
CN102100906A
(zh)
|
2011-02-18 |
2011-06-22 |
深圳翰宇药业股份有限公司 |
一种艾塞那肽的药用制剂及其制备方法
|
|
DK2683364T3
(en)
|
2011-03-10 |
2017-02-27 |
Xeris Pharmaceuticals Inc |
Stable formulations for parenteral injection of peptide drugs.
|
|
CN102718858B
(zh)
|
2011-03-29 |
2014-07-02 |
天津药物研究院 |
胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
|
|
CN102718868A
(zh)
|
2011-03-30 |
2012-10-10 |
上海华谊生物技术有限公司 |
定点单取代聚乙二醇化Exendin类似物及其制备方法
|
|
DK2694095T3
(en)
|
2011-04-05 |
2018-05-28 |
Longevity Biotech Inc |
COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
|
|
US9480751B2
(en)
|
2011-04-11 |
2016-11-01 |
Yeda Research And Development Co. Ltd. |
Albumin binding probes and drug conjugates thereof
|
|
WO2012150503A2
(en)
|
2011-05-03 |
2012-11-08 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
|
CN102766204B
(zh)
|
2011-05-05 |
2014-10-15 |
天津药物研究院 |
胰高血糖素样肽-1突变体多肽及其制备方法和其应用
|
|
CA2836574C
(en)
|
2011-05-18 |
2021-11-30 |
Mederis Diabetes, Llc |
Improved peptide pharmaceuticals for insulin resistance
|
|
WO2012162547A2
(en)
|
2011-05-25 |
2012-11-29 |
Amylin Pharmaceuticals, Inc. |
Long duration dual hormone conjugates
|
|
UA113626C2
(xx)
|
2011-06-02 |
2017-02-27 |
|
Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
|
|
CN103764673A
(zh)
|
2011-06-10 |
2014-04-30 |
北京韩美药品有限公司 |
葡萄糖依赖性促胰岛素多肽类似物、其药物组合物及应用
|
|
PH12018501954A1
(en)
|
2011-06-10 |
2023-02-13 |
Hanmi Science Co Ltd |
Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
|
|
EP2720712B1
(en)
|
2011-06-17 |
2016-03-02 |
Halozyme, Inc. |
Stable formulations of a hyaluronan-degrading enzyme
|
|
RU2733544C2
(ru)
|
2011-06-17 |
2020-10-05 |
Ханми Сайенс Ко., Лтд. |
Конъюгат, содержащий оксинтомодулин и фрагмент иммуноглобулина, и его применение
|
|
RU2014101697A
(ru)
|
2011-06-22 |
2015-07-27 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Коагонисты рецепторов глюкагона/glp-1
|
|
RS56173B1
(sr)
|
2011-06-22 |
2017-11-30 |
Univ Indiana Res & Tech Corp |
Koagonisti receptora za glukagon/glp-1 receptora
|
|
US20140220134A1
(en)
|
2011-06-24 |
2014-08-07 |
Astrazeneca Pharamceuticals LP |
Method for treating diabetes with extended release formulation of glp-1 receptor agonists
|
|
KR101357117B1
(ko)
|
2011-06-28 |
2014-02-06 |
비앤엘델리팜 주식회사 |
폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
|
|
WO2013004983A1
(en)
|
2011-07-04 |
2013-01-10 |
Imperial Innovations Limited |
Novel compounds and their effects on feeding behaviour
|
|
JP6006309B2
(ja)
|
2011-07-08 |
2016-10-12 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
|
|
EP2741765B9
(fr)
|
2011-08-10 |
2016-09-28 |
Adocia |
Solution injectable d'au moins une insuline basale
|
|
WO2013028989A1
(en)
|
2011-08-24 |
2013-02-28 |
Phasebio Pharmaceuticals, Inc. |
Formulations of active agents for sustained release
|
|
CN103189389B
(zh)
|
2011-09-03 |
2017-08-11 |
深圳市健元医药科技有限公司 |
新的glp‑ⅰ类似物及其制备方法和用途
|
|
US8541368B2
(en)
|
2011-09-23 |
2013-09-24 |
Novo Nordisk A/S |
Glucagon analogues
|
|
CA2851690C
(en)
|
2011-10-28 |
2022-07-26 |
Sanofi-Aventis Deutschland Gmbh |
Treatment protocol of diabetes type 2
|
|
CN102363633B
(zh)
|
2011-11-16 |
2013-11-20 |
天津拓飞生物科技有限公司 |
胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
|
|
BR112014007124A2
(pt)
|
2011-11-17 |
2017-06-13 |
Univ Indiana Res & Tech Corp |
superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide
|
|
ES2784629T3
(es)
|
2011-11-29 |
2020-09-29 |
Jurox Pty Ltd |
Composiciones farmacéuticas inyectables estables que comprenden 2-hidroxipropil-beta-ciclodextrina y alfaxalona
|
|
MX2014007233A
(es)
|
2011-12-16 |
2015-02-04 |
Moderna Therapeutics Inc |
Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
|
|
CA2859969A1
(en)
|
2011-12-22 |
2013-06-27 |
Pfizer Inc. |
Processes for purifying a sample of h38c2 antibody or variant thereof
|
|
AU2012357739A1
(en)
|
2011-12-23 |
2014-07-03 |
Boehringer Ingelheim International Gmbh |
Glucagon analogues
|
|
EP2797585A4
(en)
|
2011-12-29 |
2015-10-07 |
Latitude Pharmaceuticals Inc |
STABILIZED GLUCAGONNANOULULSIONS
|
|
US9198971B2
(en)
|
2012-01-09 |
2015-12-01 |
Adocia |
Injectable solution at pH 7 comprising at least one basal insulin the pI of which is between 5.8 and 8.5 and a substituted co-polyamino acid
|
|
EP2844269A4
(en)
|
2012-03-28 |
2016-01-06 |
Amylin Pharmaceuticals Llc |
TRANSMUCOSAL ADMINISTRATION OF MANIPULATED POLYPEPTIDES
|
|
WO2013148871A1
(en)
|
2012-03-28 |
2013-10-03 |
Amylin Pharmaceuticals, Llc |
Engineered polypeptides
|
|
CA2868391A1
(en)
|
2012-04-02 |
2013-10-10 |
Stephane Bancel |
Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
|
|
WO2013151663A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of membrane proteins
|
|
CN102649947A
(zh)
|
2012-04-20 |
2012-08-29 |
无锡和邦生物科技有限公司 |
一种用于测定glp-1及其功能类似物生物活性的细胞株及其应用
|
|
WO2013163162A1
(en)
|
2012-04-24 |
2013-10-31 |
Amylin Pharmaceuticals, Llc |
Site-specific enzymatic modification of exendins and analogs thereof
|
|
US20130289241A1
(en)
|
2012-04-26 |
2013-10-31 |
Shanghai Ambiopharm, Inc. |
Method for preparing exenatide
|
|
US8901484B2
(en)
|
2012-04-27 |
2014-12-02 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
|
WO2013182217A1
(en)
|
2012-04-27 |
2013-12-12 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
|
TR201802689T4
(tr)
|
2012-05-03 |
2018-03-21 |
Zealand Pharma As |
Glukagon benzeri peptit-2 (glp-2) analogları.
|
|
JP6228187B2
(ja)
|
2012-05-03 |
2017-11-08 |
ジーランド ファーマ アクティーゼルスカブ |
Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
|
|
EP2664374A1
(en)
|
2012-05-15 |
2013-11-20 |
F. Hoffmann-La Roche AG |
Lysin-glutamic acid dipeptide derivatives
|
|
CN103421094A
(zh)
|
2012-05-24 |
2013-12-04 |
上海医药工业研究院 |
一种具有epo类似活性的多肽化合物
|
|
WO2013177565A1
(en)
|
2012-05-25 |
2013-11-28 |
Amylin Pharmaceuticals, Llc |
Insulin-pramlintide compositions and methods for making and using them
|
|
JP2015525226A
(ja)
|
2012-06-14 |
2015-09-03 |
サノフイ |
エキセンディン−４ペプチドアナログ
|
|
DK2864350T3
(en)
|
2012-06-21 |
2018-05-28 |
Univ Indiana Res & Tech Corp |
ANALOGUE OF GLUCAGON EXPRESSING GIP RECEPTOR ACTIVITY
|
|
US9340600B2
(en)
|
2012-06-21 |
2016-05-17 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting GIP receptor activity
|
|
EP2872205B1
(en)
|
2012-07-12 |
2017-02-08 |
MannKind Corporation |
Dry powder drug delivery systems
|
|
UA117103C2
(uk)
|
2012-07-23 |
2018-06-25 |
Зіленд Фарма А/С |
Сполука, яка має активність агоніста глюкагону
|
|
AR092862A1
(es)
|
2012-07-25 |
2015-05-06 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
|
|
AR094821A1
(es)
|
2012-07-25 |
2015-09-02 |
Hanmi Pharm Ind Co Ltd |
Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
|
|
KR101968344B1
(ko)
|
2012-07-25 |
2019-04-12 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
|
|
WO2014027254A1
(en)
|
2012-08-14 |
2014-02-20 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
|
WO2014027253A1
(en)
|
2012-08-14 |
2014-02-20 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
|
CN102816244A
(zh)
|
2012-08-23 |
2012-12-12 |
无锡和邦生物科技有限公司 |
一种Exendin-4肽与人血清白蛋白HSA的融合蛋白及其制备方法
|
|
CN102827270A
(zh)
|
2012-09-13 |
2012-12-19 |
无锡和邦生物科技有限公司 |
一种聚乙二醇化艾塞那肽衍生物及其用途
|
|
US9546205B2
(en)
|
2012-09-17 |
2017-01-17 |
Imperial Innovations Limited |
Peptide analogues of glucagon and GLP1
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
AR092873A1
(es)
|
2012-09-26 |
2015-05-06 |
Cadila Healthcare Ltd |
Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
EP3610856B1
(en)
|
2012-11-06 |
2021-08-18 |
Hanmi Pharm. Co., Ltd. |
Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
|
|
KR101993393B1
(ko)
|
2012-11-06 |
2019-10-01 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
|
|
WO2014081872A1
(en)
|
2012-11-20 |
2014-05-30 |
Mederis Diabetes, Llc |
Improved peptide pharmaceuticals for insulin resistance
|
|
TWI617574B
(zh)
|
2012-12-11 |
2018-03-11 |
梅迪繆思有限公司 |
用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
|
|
JP6408998B2
(ja)
|
2012-12-21 |
2018-10-17 |
サノフイＳａｎｏｆｉ |
二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニスト
|
|
CN103908657A
(zh)
|
2012-12-31 |
2014-07-09 |
复旦大学附属华山医院 |
胰升糖素样肽-1类似物在制备眼科疾病药物中的用途
|
|
WO2014140222A1
(en)
|
2013-03-14 |
2014-09-18 |
Medimmune Limited |
Pegylated glucagon and glp-1 co-agonists for the treatment of obesity
|
|
CN105324397B
(zh)
|
2013-03-14 |
2020-01-14 |
印第安纳大学研究及科技有限公司 |
胰岛素-肠促胰岛素缀合物
|
|
EP2986314A4
(en)
|
2013-03-15 |
2016-04-13 |
Univ Indiana Res & Tech Corp |
PRODRUGS WITH EXTENDED EFFECT
|
|
AU2014255608B2
(en)
|
2013-04-18 |
2018-01-25 |
Novo Nordisk A/S |
Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
|
|
JP2014227368A
(ja)
|
2013-05-21 |
2014-12-08 |
国立大学法人帯広畜産大学 |
糖尿病および高血糖状態の処置のためのグルカゴンアナログ
|
|
CN103304660B
(zh)
|
2013-07-12 |
2016-08-10 |
上海昂博生物技术有限公司 |
一种利拉鲁肽的合成方法
|
|
CN103405753B
(zh)
|
2013-08-13 |
2016-05-11 |
上海仁会生物制药股份有限公司 |
稳定的促胰岛素分泌肽水针药物组合物
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
BR112016008115B1
(pt)
|
2013-10-17 |
2024-03-12 |
Boehringer Ingelheim International Gmbh |
Análogos de glucagon acilados
|
|
WO2015067716A1
(en)
|
2013-11-06 |
2015-05-14 |
Zealand Pharma A/S |
Glucagon-glp-1-gip triple agonist compounds
|
|
EP3080151A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Exendin-4 peptide analogues
|
|
TW201609799A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重ｇｌｐ－１／ｇｉｐ受體促效劑
|
|
WO2015086728A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
EP3080149A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
|
WO2015086730A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
|
WO2015086731A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
|
|
CN103665148B
(zh)
|
2013-12-17 |
2016-05-11 |
中国药科大学 |
一种可口服给药的降糖多肽及其制法和用途
|
|
CN103980358B
(zh)
|
2014-01-03 |
2016-08-31 |
杭州阿诺生物医药科技股份有限公司 |
一种制备利拉鲁肽的方法
|
|
CN112957455A
(zh)
|
2014-01-09 |
2021-06-15 |
赛诺菲 |
胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
|
|
SG11201604708VA
(en)
|
2014-01-09 |
2016-07-28 |
Sanofi Sa |
Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
|
GB201404002D0
(en)
|
2014-03-06 |
2014-04-23 |
Imp Innovations Ltd |
Novel compounds
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
CN104926934B
(zh)
|
2014-09-23 |
2016-11-09 |
蒋先兴 |
胃泌酸调节素类似物
|
|
WO2016055610A1
(en)
|
2014-10-10 |
2016-04-14 |
Novo Nordisk A/S |
Stable glp-1 based glp-1/glucagon receptor co-agonists
|
|
WO2016065090A1
(en)
|
2014-10-24 |
2016-04-28 |
Merck Sharp & Dohme Corp. |
Co-agonists of the glucagon and glp-1 receptors
|
|
WO2016198604A1
(en)
|
2015-06-12 |
2016-12-15 |
Sanofi |
Exendin-4 derivatives as dual glp-1 /glucagon receptor agonists
|
|
WO2016198624A1
(en)
|
2015-06-12 |
2016-12-15 |
Sanofi |
Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
|